作者
Erica Hlavin Bell, Stephanie L Pugh, Joseph P McElroy, Mark R Gilbert, Minesh Mehta, Alexander C Klimowicz, Anthony Magliocco, Markus Bredel, Pierre Robe, Anca-L Grosu, Roger Stupp, Walter Curran, Aline P Becker, Andrea L Salavaggione, Jill S Barnholtz-Sloan, Kenneth Aldape, Deborah T Blumenthal, Paul D Brown, Jon Glass, Luis Souhami, R Jeffrey Lee, David Brachman, John Flickinger, Minhee Won, Arnab Chakravarti
发表日期
2017/6/1
期刊
JAMA oncology
卷号
3
期号
6
页码范围
784-792
出版商
American Medical Association
简介
Importance
There is a need for a more refined, molecularly based classification model for glioblastoma (GBM) in the temozolomide era.
Objective
To refine the existing clinically based recursive partitioning analysis (RPA) model by incorporating molecular variables.
Design, Setting, and Participants
NRG Oncology RTOG 0525 specimens (n = 452) were analyzed for protein biomarkers representing key pathways in GBM by a quantitative molecular microscopy-based approach with semiquantitative immunohistochemical validation. Prognostic significance of each protein was examined by single-marker and multimarker Cox regression analyses. To reclassify the prognostic risk groups, significant protein biomarkers on single-marker analysis were incorporated into an RPA model consisting of the same clinical variables (age, Karnofsky Performance Status, extent of resection, and neurologic function) as the existing …
学术搜索中的文章
EH Bell, SL Pugh, JP McElroy, MR Gilbert, M Mehta… - JAMA oncology, 2017